10.51

2.84% 0.29

After Hours: 10.50 -0.010 -0.10%

Atara Biotherapeutics Inc (ATRA)

Overview News Price History Option Chain Financials Why ATRA Down? Discussions Forecast

Atara Biotherapeutics Inc stock is traded at $10.51, with a volume of 45,295. It is up +2.84% in the last 24 hours and up +9.37% over the past month. Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.

Previous Close:

$10.22

Open:

$10.2

24h Volume:

45,295

Relative Volume:

0.03

Market Cap:

$94.70M

Revenue:

$23.14M

Net Income/Loss:

$-9.47M

P/E Ratio:

-11.91

EPS:

-0.8827

Net Cash Flow:

$-25.88M

1W Performance:

+4.37%

1M Performance:

+9.37%

6M Performance:

-39.14%

1Y Performance:

+32.20%

1-Day Range:

$10.15

$10.71

1-Week Range:

$9.66

$11.55

52-Week Range:

$3.92

$19.14

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Name

Atara Biotherapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (615)

Phone

805-623-4211

Address

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Employee

Twitter

@Atarabio

Next Earnings Date

2026-08-10

Latest SEC Filings

ATRA's Discussions on Twitter

Compare ATRA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATRA Atara Biotherapeutics Inc	10.51	92.08M	23.14M	-9.47M	-25.88M	-0.8827
VRTX Vertex Pharmaceuticals Inc	491.34	121.87B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	632.90	65.01B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	887.18	55.26B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	291.37	39.14B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	182.08	37.88B	742.00K	-1.37B	-1.07B	-7.0731

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-26	Downgrade	Canaccord Genuity	Buy → Hold
Nov-09-23	Downgrade	Evercore ISI	Outperform → In-line
Nov-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-23	Downgrade	Mizuho	Buy → Neutral
Jul-20-22	Downgrade	Citigroup	Neutral → Sell
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral
Jul-13-22	Downgrade	Stifel	Buy → Hold
May-10-22	Downgrade	Citigroup	Buy → Neutral
May-13-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-09-20	Downgrade	Citigroup	Buy → Neutral
Dec-08-20	Reiterated	H.C. Wainwright	Buy
Nov-10-20	Reiterated	H.C. Wainwright	Buy
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy
Apr-23-20	Upgrade	Citigroup	Neutral → Buy
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral
Sep-27-19	Downgrade	Goldman	Neutral → Sell
Sep-16-19	Downgrade	Jefferies	Buy → Hold
Jun-04-19	Upgrade	Citigroup	Sell → Neutral
May-30-19	Initiated	ROTH Capital	Buy
May-23-19	Initiated	Stifel	Buy
Jan-23-19	Initiated	Mizuho	Buy
Apr-10-18	Initiated	JP Morgan	Overweight
Mar-16-18	Initiated	Guggenheim	Neutral
Mar-05-18	Reiterated	Jefferies	Buy
Feb-28-18	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-15-18	Downgrade	Citigroup	Neutral → Sell
Jan-03-18	Upgrade	Citigroup	Sell → Neutral
Oct-06-17	Resumed	Goldman	Neutral

View All

Atara Biotherapeutics Inc Stock (ATRA) Latest News

04:16 AM

Atara Biotherapeutics (NASDAQ: ATRA) appoints CRCFO consultant as interim CFO - Stock Titan

04:16 AM

05:19 AM

Atara Biotherapeutics Inc Actuals & Estimates (NASDAQ:ATRA) - TradingView

05:19 AM

Jun 25, 2026

ATRA Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Jun 25, 2026

Jun 24, 2026